Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
EUCR Stock Summary
In the News
EUCR Financial details
Company Rating
Strong Buy
Market Cap
42.23M
Income
5.44M
Revenue
0
Book val./share
2.86
Cash/share
4.15
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Mar 2021
P/E
16
Forward P/E
-
PEG
-2.79
P/S
-
P/B
10.2
P/C
-
P/FCF
-67
Quick Ratio
189.93
Current Ratio
2.03
Debt / Equity
0.01
LT Debt / Equity
-
-
-
EPS (TTM)
0.55
EPS next Y
-
EPS next Q
-
EPS this Y
45.31%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
100.22%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
3.39%
Inst Trans
0.99%
ROA
44%
ROE
7%
ROC
-0.06%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
4.21M
Shs Float
1.59M
-
-
-
-
Target Price
-
52W Range
9.87-10.25
52W High
-
52W Low
-
RSI
-
Rel Volume
7.64
Avg Volume
1.66K
Volume
-
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
-
-
-
-
-
Beta
-0.074239
-
-
Volatility
0%, 0%
Prev Close
-
Price
-
Change
-
EUCR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
Metric | History | 2020-12-31 | 2021-12-31 | 2022-12-31 |
---|---|---|---|---|
2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | |
Net income per share | 0 | 0.28 | 1.86 | |
Operating cash flow per share | 0 | -0.04 | -0.21 | |
Free cash flow per share | 0 | -0.04 | -0.21 | |
Cash per share | 0.04 | 0 | 4.15 | |
Book value per share | 7.59 | 7.38 | 2.86 | |
Tangible book value per share | 7.59 | 7.38 | 2.86 | |
Share holders equity per share | 7.59 | 7.38 | 2.86 | |
Interest debt per share | 0 | 0 | -1.03 | |
Market cap | 135.26M | 131.36M | 29.77M | |
Enterprise value | 134.71M | 131.31M | 29.81M | |
P/E ratio | 15.74K | 34.35 | 5.37 | |
Price to sales ratio | 0 | 0 | 0 | |
POCF ratio | 0 | -261.62 | -47.22 | |
PFCF ratio | 0 | -261.62 | -47.22 | |
P/B Ratio | 1.32 | 1.32 | 3.49 | |
PTB ratio | 1.32 | 1.32 | 3.49 | |
EV to sales | 0 | 0 | 0 | |
Enterprise value over EBITDA | 15.68K | -24.9 | -11.57 | |
EV to operating cash flow | 0 | -261.52 | -47.29 | |
EV to free cash flow | 0 | -261.52 | -47.29 | |
Earnings yield | 0 | 0.03 | 0.19 | |
Free cash flow yield | 0 | 0 | -0.02 | |
Debt to equity | 0 | 0 | 0.01 | |
Debt to assets | 0 | 0 | 0 | |
Net debt to EBITDA | -64.15 | 0.01 | -0.02 | |
Current ratio | 19.42 | 6.87 | 2.03 | |
Interest coverage | 0 | 0 | 0.22 | |
Income quality | 0 | -0.13 | -0.26 | |
Dividend Yield | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | |
Graham number | 0.33 | 6.87 | 10.95 | |
ROIC | 0 | -0.01 | -0.19 | |
Return on tangible assets | 0 | 0.04 | 0.44 | |
Graham Net | -0.24 | -0.43 | 2.83 | |
Working capital | 968.77K | 225.7K | 67.06K | |
Tangible asset value | 102.11M | 99.31M | 8.54M | |
Net current asset value | -2.7M | -5.54M | -3.82M | |
Invested capital | 0 | 0 | 0.01 | |
Average receivables | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | |
ROE | 0 | 0.04 | 0.65 | |
Capex per share | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q4
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0.69 | 0.21 | 0.07 | 0.09 | 0.18 | |
Operating cash flow per share | -0.08 | -0.01 | 0 | 0 | -0.13 | |
Free cash flow per share | -0.08 | -0.01 | 0 | 0 | -0.13 | |
Cash per share | 0.01 | 0.01 | 0.01 | 0 | 4.15 | |
Book value per share | -1.3 | 7.48 | 7.51 | 7.55 | 2.86 | |
Tangible book value per share | 23.57 | 7.48 | 7.51 | 7.55 | 2.86 | |
Share holders equity per share | -1.3 | 7.48 | 7.51 | 7.55 | 2.86 | |
Interest debt per share | -0.4 | -0.09 | -0.02 | -0.05 | -0.12 | |
Market cap | 41.13M | 132.44M | 133.25M | 134.86M | 29.77M | |
Enterprise value | 41.08M | 132.46M | 133.33M | 134.86M | 29.81M | |
P/E ratio | 3.55 | 11.91 | 36.8 | 27.87 | 13.61 | |
Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
POCF ratio | -123.1 | -945.43 | -2.45K | -3.02K | -76.09 | |
PFCF ratio | -123.1 | -945.43 | -2.45K | -3.02K | -76.09 | |
P/B Ratio | -7.49 | 1.32 | 1.32 | 1.33 | 3.49 | |
PTB ratio | -7.49 | 1.32 | 1.32 | 1.33 | 3.49 | |
EV to sales | 0 | 0 | 0 | 0 | 0 | |
Enterprise value over EBITDA | 34.24 | -90.15 | -233.34 | -265.16 | -1.14K | |
EV to operating cash flow | -122.95 | -945.62 | -2.46K | -3.02K | -76.2 | |
EV to free cash flow | -122.95 | -945.62 | -2.46K | -3.02K | -76.2 | |
Earnings yield | 0.07 | 0.02 | 0.01 | 0.01 | 0.02 | |
Free cash flow yield | -0.01 | 0 | 0 | 0 | -0.01 | |
Debt to equity | 0 | 0 | 0 | 0 | 0.01 | |
Debt to assets | 0 | 0 | 0 | 0 | 0 | |
Net debt to EBITDA | -0.04 | -0.02 | -0.14 | -0.01 | -1.57 | |
Current ratio | 0 | 1.81 | 1.1 | 0.81 | 2.03 | |
Interest coverage | 0.29 | 0.09 | 0.29 | 0.24 | 0.65 | |
Income quality | -0.28 | -0.11 | -0.13 | -0.09 | -2.76 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 4.49 | 5.9 | 3.37 | 3.91 | 3.44 | |
ROIC | 0.22 | 0 | 0 | 0 | -0.12 | |
Return on tangible assets | 0.03 | 0.03 | 0.01 | 0.01 | 0.04 | |
Graham Net | -1.36 | -0.33 | -0.3 | -0.29 | 2.83 | |
Working capital | 264.16K | 158.96K | 20.28K | -22.56K | 67.06K | |
Tangible asset value | 99.31M | 100.63M | 101.06M | 101.58M | 8.54M | |
Net current asset value | -5.54M | -4.19M | -3.89M | -3.83M | -3.82M | |
Invested capital | 0 | 0 | 0 | 0 | 0.01 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.53 | 0.03 | 0.01 | 0.01 | 0.06 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
EUCR Frequently Asked Questions
What is Eucrates Biomedical Acquisition Corp. stock symbol ?
Eucrates Biomedical Acquisition Corp. is a US stock , located in New york of Ny and trading under the symbol EUCR
What is Eucrates Biomedical Acquisition Corp. stock quote today ?
Eucrates Biomedical Acquisition Corp. stock price is $- today.
Is Eucrates Biomedical Acquisition Corp. stock public?
Yes, Eucrates Biomedical Acquisition Corp. is a publicly traded company.